These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 30648791)

  • 1. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis.
    Zhuang C; Zhuang C; Luo X; Huang X; Yao L; Li J; Li Y; Xiong T; Ye J; Zhang F; Gui Y
    J Cell Mol Med; 2019 Mar; 23(3):2163-2173. PubMed ID: 30648791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTO is required for myogenesis by positively regulating mTOR-PGC-1α pathway-mediated mitochondria biogenesis.
    Wang X; Huang N; Yang M; Wei D; Tai H; Han X; Gong H; Zhou J; Qin J; Wei X; Chen H; Fang T; Xiao H
    Cell Death Dis; 2017 Mar; 8(3):e2702. PubMed ID: 28333151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase C beta relieves autism-like behavior in EN2 knockout mice via upregulation of the FTO/PGC-1α/UCP1 axis.
    Song X; Hu Q; Xu X; Pan W
    J Biochem Mol Toxicol; 2023 Jan; 37(1):e23236. PubMed ID: 36239013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival.
    Zhao J; Lu L
    Recent Pat Anticancer Drug Discov; 2021; 16(3):363-376. PubMed ID: 33563180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The m
    Xiao Y; Thakkar KN; Zhao H; Broughton J; Li Y; Seoane JA; Diep AN; Metzner TJ; von Eyben R; Dill DL; Brooks JD; Curtis C; Leppert JT; Ye J; Peehl DM; Giaccia AJ; Sinha S; Rankin EB
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21441-21449. PubMed ID: 32817424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability.
    Xu Y; Zhou J; Li L; Yang W; Zhang Z; Zhang K; Ma K; Xie H; Zhang Z; Cai L; Gong Y; Gong K
    Int J Biol Sci; 2022; 18(15):5943-5962. PubMed ID: 36263177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPC1 is essential for PGC-1α-induced mitochondrial respiration and biogenesis.
    Koh E; Kim YK; Shin D; Kim KS
    Biochem J; 2018 May; 475(10):1687-1699. PubMed ID: 29669911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant activation of m6A demethylase FTO renders HIF2α
    Zhang C; Chen L; Lou W; Su J; Huang J; Liu A; Xu Y; He H; Gao Y; Xu D; Li Q
    Sci Transl Med; 2021 Sep; 13(613):eabf6045. PubMed ID: 34586831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1/IQGAP2/AKT signaling pathway.
    Tan D; Miao D; Zhao C; Shi J; Lv Q; Lu F; Ruan H; Xiong Z; Zhang X
    Cell Death Dis; 2024 Jul; 15(7):520. PubMed ID: 39039052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTO/IGF2BP2-mediated N6 methyladenosine modification in invasion and metastasis of thyroid carcinoma via CDH12.
    Chen Z; Zhong X; Xia M; Liu C; Tang W; Liu G; Yi Y; Guo Y; Jiang Q; Zu X; Zhong J
    Cell Death Dis; 2024 Oct; 15(10):733. PubMed ID: 39379360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma.
    LaGory EL; Wu C; Taniguchi CM; Ding CC; Chi JT; von Eyben R; Scott DA; Richardson AD; Giaccia AJ
    Cell Rep; 2015 Jul; 12(1):116-127. PubMed ID: 26119730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-155 regulates m
    Yang W; Xie L; Wang P; Zhuang C
    Cell Signal; 2022 Mar; 91():110217. PubMed ID: 34921979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
    Song W; Yang K; Luo J; Gao Z; Gao Y
    Aging (Albany NY); 2021 Jan; 13(3):3909-3925. PubMed ID: 33461172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FTO suppresses hepatocellular carcinoma by inhibiting ERBB3 and TUBB4A expression.
    Jiang L; Liang R; Luo Q; Chen Z; Song G
    Biochem Pharmacol; 2024 Aug; 226():116375. PubMed ID: 38906227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer.
    Wu J; Wang X; Li X
    Epigenomics; 2022 Dec; 14(23):1509-1522. PubMed ID: 36815224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The m
    He Y; Chen Y; Li Z; Wu C
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):30. PubMed ID: 38270643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma.
    Cui Y; Zhang C; Ma S; Li Z; Wang W; Li Y; Ma Y; Fang J; Wang Y; Cao W; Guan F
    J Exp Clin Cancer Res; 2021 Sep; 40(1):294. PubMed ID: 34544449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased N6-methyladenosine causes infertility is associated with FTO expression.
    Ding C; Zou Q; Ding J; Ling M; Wang W; Li H; Huang B
    J Cell Physiol; 2018 Sep; 233(9):7055-7066. PubMed ID: 29384212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
    Wang J; Fu Q; Yang J; Liu JL; Hou SM; Huang X; Cao JS; Liu TL; Wang KZ
    Aging (Albany NY); 2021 Sep; 13(17):21134-21141. PubMed ID: 34496349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.